Crescent Biopharma, Inc. Common Stock CBIO
Analyst Ratings
- Consensus
- Moderate Buy — 2 Buy · 1 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $31.00 (+84.9% upside)
Key Stats
- Today's Range
- $16.32 – $18.57
- 50-Day Range
- $13.99 – $22.33
- 52-Week Range
- $8.72 – $27.41
- Volume
- 666K shs
- Average Volume
- 275K shs
- Market Cap
- $622.95 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.37
- Price / Sales
- 5.22
Short Interest
- Short Interest
- 1.64%
- Days to Cover
- 1.27
Financials (TTM)
- Revenue
- $119.38 million
- Net Income
- $-20,897,000
- Net Margin
- -17.50%
- Return on Equity
- -14.67%
- Debt-to-Equity
- —
About Crescent Biopharma, Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Related Stocks
Compare head-to-head: CBIO vs LLY·CBIO vs JNJ·CBIO vs ABBV·CBIO vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.